Loading...
Prostate cancer is a highly bone-tropic neoplasm, as illustrated by the near universal presence of bone metastases in men dying of the disease. Drug development for prevention of bone metastases has been focused largely on prevention or delay of skeletal-related events (SREs), which include pathologic fracture, spinal-cord compression, bone pain, and the need for radiation therapy or surgery in patients with castration-resistant metastatic disease. One agent that was found to be superior in delaying the time to SREs when compared to the bisphosphonate zoledronic acid is denosumab, a human monoclonal antibody that binds and inactivates RANK ligand (RANKL), which mediates the interaction between osteoblasts and osteoclasts (JW Oncol Hematol A…